Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 10
Submit an article Journal homepage
374
Views
63
CrossRef citations to date
0
Altmetric
Review

Chromatin-modifying enzymes as therapeutic targets – Part 1

Brian R Keppler National Institute of Environmental Health Sciences, National Institutes of Health, North Carolina 27709, USA [email protected]
&
Trevor K Archer National Institute of Environmental Health Sciences, National Institutes of Health, North Carolina 27709, USA [email protected]
Pages 1301-1312 | Published online: 09 Sep 2008

Bibliography

  • Kornberg RD, Thomas JO. Chromatin structure; oligomers of the histones. Science 1974;184(139):865-8
  • Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-80
  • Kornberg RD, Lorch Y. Chromatin structure and transcription. Ann Rev Cell Biol 1992;8:563-87
  • Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997;389(6648):251-60
  • Van Holde K, Zlatanova J. What determines the folding of the chromatin fiber? Proc Natl Acad Sci USA 1996;93(20):10548-55
  • Bottomley MJ. Structures of protein domains that create or recognize histone modifications. EMBO Rep 2004;5(5):464-9
  • Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 2004;26(10):1076-87
  • Brehm A, Tufteland KR, Aasland R, Becker PB. The many colours of chromodomains. Bioessays 2004;26(2):133-40
  • Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Ann Rev Biochem 1998;67:545-79
  • Schotta G, Lachner M, Sarma K, et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004;18(11):1251-62
  • Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci USA 1999;96(26):14967-72
  • Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci USA 2004;101(19):7357-62
  • Dorigo B, Schalch T, Bystricky K, Richmond TJ. Chromatin fiber folding: requirement for the histone H4 N-terminal tail. J Mol Biol 2003;327(1):85-96
  • Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3(6):415-28
  • Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 2007;97(1):1-5
  • Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262-6
  • Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007;11(6):835-51
  • Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16(5):659-78
  • Stavropoulos P, Hoelz A. Lysine-specific demethylase 1 as a potential therapeutic target. Expert Opin Ther Targets 2007;11(6):809-20
  • Luger K, Richmond TJ. The histone tails of the nucleosome. Curr Opin Genet Dev 1998;8(2):140-6
  • Puri PL, Sartorelli V, Yang XJ, et al. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997;1(1):35-45
  • Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 2004;32(3):959-76
  • Stein RW, Corrigan M, Yaciuk P, et al. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity. J Virol 1990;64(9):4421-7
  • Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24(3):300-3
  • Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995;376(6538):348-51
  • Rouaux C, Loeffler JP, Boutillier AL. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol 2004;68(6):1157-64
  • Ikura T, Ogryzko VV, Grigoriev M, et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000;102(4):463-73
  • Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277(5328):965-8
  • Borrow J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14(1):33-41
  • Cullis PM, Wolfenden R, Cousens LS, Alberts BM. Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog. J Biol Chem 1982;257(20):12165-9
  • Lau OD, Kundu TK, Soccio RE, et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000;5(3):589-95
  • Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003;278(21):19134-40
  • Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004;279(32):33716-26
  • Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279(49):51163-71
  • Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Ann Rev Biochem 2001;70:81-120
  • Denu JM. Linking chromatin function with metabolic networks: Sir2 family of NAD+-dependent deacetylases. Trends Biochem Sci 2003;28(1):41-8
  • Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998;391(6667):597-601
  • McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002;27(1):40-7
  • Gruffat H, Manet E, Sergeant A. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep 2002;3(2):141-6
  • Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107(2):149-59
  • Weston AD, Blumberg B, Underhill TM. Active repression by unliganded retinoid receptors in development: less is sometimes more. J Cell Biol 2003;161(2):223-8
  • Hong SH, David G, Wong CW, et al. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94(17):9028-33
  • Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene 2002;21(21):3422-44
  • Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5(5):455-63
  • Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38(5):566-9
  • Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10(20):6962-8
  • Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101(5):1241-6
  • Espino PS, Drobic B, Dunn KL, Davie JR. Histone modifications as a platform for cancer therapy. J Cell Biochem 2005;94(6):1088-102
  • Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46(24):5097-116
  • Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18(50):7016-25
  • Hirsch CL, Bonham K. Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett 2004;570(1-3):37-40
  • Sandor V, Senderowicz A, Mertins S, et al. P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83(6):817-25
  • Wharton W, Savell J, Cress WD, et al. Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem 2000;275(43):33981-7
  • Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-88
  • Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101(2):540-5
  • Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5(4-5):245-53
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
  • Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92(2):223-37
  • Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4(1):13-8
  • Demonte D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 2004;68(6):1231-8
  • McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000;408(6808):106-11
  • Valk-Lingbeek ME, Bruggeman SW, Van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004;118(4):409-18
  • Bannister AJ, Zegerman P, Partridge JF, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001;410(6824):120-4
  • Lachner M, O'Carroll D, Rea S, et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001;410(6824):116-20
  • He L, Yu JX, Liu L, et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 1998;58(19):4238-44
  • Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002;10(5):1107-17
  • Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007;9(7):804-12
  • Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22(20):5323-35
  • Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100(20):11606-11
  • Kirmizis A, Bartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2(1):113-21
  • Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005;436(7051):660-5
  • Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001;107(3):323-37
  • Derunes C, Briknarova K, Geng L, et al. Characterization of the PR domain of RIZ1 histone methyltransferase. Biochem Biophys Res Commun 2005;333(3):925-34
  • So CW, Lin M, Ayton PM, et al. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003;4(2):99-110
  • Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20(40):5695-707
  • Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6(8):731-40
  • Hong H, Kao C, Jeng MH, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004;101(1):83-9
  • Fabbrizio E, El Messaoudi S, Polanowska J, et al. Negative regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO Rep 2002;3(7):641-5
  • Boulanger MC, Liang C, Russell RS, et al. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol 2005;79(1):124-31
  • Schneider R, Bannister AJ, Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002;27(8):396-402
  • Sims RJ 3rd, Reinberg D. From chromatin to cancer: a new histone lysine methyltransferase enters the mix. Nat Cell Biol 2004;6(8):685-7
  • Greiner D, Bonaldi T, Eskeland R, et al. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005;1(3):143-5
  • Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 2004;279(23):23892-9
  • Skillman AG, Maurer KW, Roe DC, et al. A novel mechanism for inhibition of HIV-1 reverse transcriptase. Bioorg Chem 2002;30(6):443-58
  • Mai A, Cheng D, Bedford MT, et al. Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem 2008;51(7):2279-90
  • An W, Kim J, Roeder RG. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 2004;117(6):735-48
  • Altaf M, Utley RT, Lacoste N, et al. Interplay of chromatin modifiers on a short basic patch of histone H4 tail defines the boundary of telomeric heterochromatin. Mol Cell 2007;28(6):1002-14
  • Brachmann CB, Sherman JM, Devine SE, et al. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev 1995;9(23):2888-902
  • Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121(2):167-78
  • So CW, Cleary ML. Dimerization: a versatile switch for oncogenesis. Blood 2004;104(4):919-22
  • Forneris F, Binda C, Vanoni MA, et al. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett 2005;579(10):2203-7
  • Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006;439(7078):811-6
  • Cuthbert GL, Daujat S, Snowden AW, et al. Histone deimination antagonizes arginine methylation. Cell 2004;118(5):545-53
  • Wang Y, Wysocka J, Sayegh J, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004;306(5694):279-83
  • Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119(7):941-53
  • Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005;437(7057):436-9
  • Lee MG, Wynder C, Bochar DA, et al. Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol 2006;26(17):6395-402
  • Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66(23):11341-7
  • Lee MG, Wynder C, Schmidt DM, et al. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006;13(6):563-7
  • Culhane JC, Szewczuk LM, Liu X, et al. A mechanism-based inactivator for histone demethylase LSD1. J Am Chem Soc 2006;128(14):4536-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.